Oxaliplatin Kalceks (Oxaliplatin)

Oxaliplatin Kalceks is a platinum‑based chemotherapeutic that interferes with DNA replication in rapidly growing cancer cells.

• Colorectal cancer: improves overall treatment outcomes when used in combination regimens.
• Gastric cancer: contributes to tumour shrinkage as part of multi‑drug protocols.
• Pancreatic cancer: used in combination therapies to enhance response rates.
• Ovarian cancer : aids in disease control when combined with taxanes.
• Advanced solid tumours : provides clinical benefit in selected treatment‑resistant cases.

• Oxaliplatin exerts its anticancer activity by forming reactive platinum‑DNA adducts that distort the DNA helix, blocking replication and transcription. This triggers cellular apoptosis pathways, particularly in rapidly dividing tumour cells, while sparing most normal tissues.

Oxaliplatin Kalceks may induce a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Peripheral neuropathy: tingling or numbness, often reversible after treatment.
• Diarrhoea: loose stools that may require supportive care.
• Fatigue: generalised tiredness during therapy cycles.
• Thrombocytopenia: reduced platelet count, increasing bleed risk.
• Elevated liver enzymes: transient rise in hepatic function tests.

Serious or Rare Side Effects

• Severe hypersensitivity: rash, bronchospasm or anaphylaxis.
• Acute neurotoxicity: sudden onset of muscle cramps or jaw tightness.
• Persistent peripheral neuropathy: long‑term sensory deficits.
• Hemolytic‑type reactions: rapid drop in red blood cells.
• Cardiac arrhythmias: irregular heart rhythm requiring monitoring.
• Renal impairment: acute kidney injury in susceptible patients.

When handling Oxaliplatin Kalceks, clinicians should observe specific safety measures to minimise risks to patients and staff.

• Pre‑treatment assessment: evaluate renal and hepatic function, and review baseline neuropathy.
• Hydration status: ensure adequate intravenous fluids to reduce renal toxicity.
• Concomitant neurotoxic drugs: avoid or adjust doses of other agents that may worsen neuropathy.
• Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with obstetric specialist.
• Monitoring: perform regular complete blood counts and liver function tests during therapy.
• Store at below 25°C: keep in the original packaging, protect from light and moisture.

Oxaliplatin may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of kidney injury.
• Anticoagulants (warfarin, heparin): heighten bleeding risk when thrombocytopenia occurs.
• High‑dose vitamin C: may reduce platinum‑DNA binding efficacy.

Moderate Interactions (Monitor Closely)

• Other neurotoxic chemotherapy (e.g., paclitaxel): may amplify peripheral neuropathy.
• CYP450 inducers (rifampicin, carbamazepine): potential modest‑level       

decrease  the  met‑   ...